Abstract
Many tumor suppressor genes are known to function at least in part through regulation of the transcription of downstream effector genes (Table 1). A major example of such a transcriptional regulator is p53, one of the most commonly mutated tumor suppressor genes in human cancer (1) and hence one of the most exhaustively studied. Estimates based on a survey of p53 binding sites in the genome put the number of p53-regulated genes at several hundred (2), while the finding that p53 can affect the expression of some genes in the absence of direct DNA binding may increase this number (3). Genes known to be regulated by p53 play roles in many important cellular processes, including cell cycle progression, DNA repair, and apoptosis (Table 2). Loss of such a tumor suppressor gene can disrupt the regulation of multiple genes, affecting numerous cellular pathways and leading to a variety of phenotypic changes. Comparative analysis of complex patterns of gene expression can therefore provide a powerful tool to develop insight into mechanisms of tumor suppressor gene function involving transcriptional regulation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Levine, A. J., Momand J., and Finlay, C. A. (1991) The p53 tumor suppressor gene. Nature 351, 453–456.
Hartwell, L. H. and Kastan, M. B. (1994) Cell cycle control and cancer. Science 266, 1821–1828.
Zhan, Q., Chen, I. T, Antinore, M. J., and Fornace, A. J., Jr. (1998) Tumor suppressor p53 can participate in transcriptional induction of the GADD45 promoter in the absence of direct DNA binding. Mol. Cell. Biol. 18, 2768–2778.
Velculescu, V. E., Zhang, L., Vogelstein, B., and Kinzler, K. W. (1995) Serial analysis of gene expression. Science 270, 484–487.
Fargnoli, J., Holbrook, N. J., and Fornace, A. J., Jr. (1990) Low-ratio hybridization subtraction. Anal. Biochem. 187, 364–373.
Schena, M., Shalon, D., Davis, R. W., and Brown, P. O. (1995) Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270, 467–470.
Lockhart, D. J., Dong, H., Byrne, M. C., et al. (1996) Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat. Biotechnol. 14, 1675–1680.
Okamoto, T., Suzuki, T., and Yamamoto, N. (2000) Microarray fabrication with covalent attachment of DNA using bubble jet technology. Nat. Biotechnol. 18, 438–441.
Medlin, J. (2001) Array of hope for gene technology. Environ. Health Perspect. 109, A34–A37.
Shoemaker, D. D., Schadt, E. E., Armour, C. D., et al. (2001) Experimental annotation of the human genome using microarray technology. Nature 409, 922–927.
DeRisi, J., Penland, L., Brown, P. O., et al. (1996) Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat. Genet. 14, 457–460.
Koch-Paiz, C. A., Momenan, R., Amundson, S. A., Lamoreaux, E., and Fornace, A. J., Jr. (2000) Estimation of relative mRNA content by filter hybridization to a polyuridylic probe. Biotechniques 29, 706–714.
Eisen, M. B., Spellman, P. T., Brown, P. O., and Botstein, D. (1998) Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 95, 14863–14868.
Alon, U., Barkai, N., Notterman, D. A., et al. (1999) Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc. Natl. Acad. Sci. USA 96, 6745–6750.
Alizadeh, A. A., Eisen, M. B., Davis, R. E., et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [see comments]. Nature 403, 503–511.
Bittner, M., Meltzer, P., Chen, Y., et al. (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406, 536–540.
Hedenfalk, I., Duggan, D., Chen, Y., et al. (2001) Gene-expression profiles in hereditary breast cancer. N. Engl. J. Med. 344, 539–548.
Monks, A., Scudiero, D., Skehan, P., et al. (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 83, 757–766.
Grever, M. R., Schepartz, S. A., and Chabner, B. A. (1992) The National Cancer Institute: cancer drug discovery and development program. Semin. Oncol. 19, 622–638.
Ross, D. T., Scherf, U., Eisen, M. B., et al. (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24, 227–235.
Mai, M., Yokomizo, A., Qian, C., et al. (1998) Activation of p73 silent allele in lung cancer. Cancer Res. 58, 2347–2349.
Scherf, U., Ross, D. T., Waltham, M., et al. (2000) A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24, 236–244.
O’Connor, P. M., Jackman, J., Bae, I., et al. (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57, 4285–4300.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc.
About this protocol
Cite this protocol
Amundson, S.A., Fornace, A.J. (2003). Microarray Approaches for Analysis of Tumor Suppressor Gene Function. In: El-Deiry, W.S. (eds) Tumor Suppressor Genes. Methods in Molecular Biology™, vol 223. Humana Press. https://doi.org/10.1385/1-59259-329-1:141
Download citation
DOI: https://doi.org/10.1385/1-59259-329-1:141
Publisher Name: Humana Press
Print ISBN: 978-0-89603-987-2
Online ISBN: 978-1-59259-329-3
eBook Packages: Springer Protocols